XML 38 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity (Tables)
9 Months Ended 12 Months Ended
Sep. 30, 2018
Dec. 31, 2017
Equity [Abstract]    
Schedule of assumptions used in Black-Scholes pricing model to estimate the fair value of the options granted
   Nine Months
Ended
 
   September 30, 
   2018 
Expected volatility   159.0-167.0%
Expected life of option (years)   5.2-6.3 
Risk free interest rate   2.3-2.9%
Expected dividend yield   0.0%

    December 31,  
    2017     2016  
Expected volatility     116.1-159.0 %     76.6-139.2 %
Expected life of option     5.0-7.0       5.5  
Risk free interest rate     1.7-2.2 %     1.1-1.8 %
Expected dividend yield     0.0 %     0.0 %

Schedule of stock option activity
       Weighted 
   Number of   Average
Exercise
 
   Options   Price 
Stock Options:        
Outstanding at January 1, 2018   980,588   $5.02 
Granted   120,130    5.95 
Exercised, during period   (6,363)   4.43 
Expired or canceled, during the period   (1,429)   42.35 
Forfeited, during the period   (25,399)   4.45 
Outstanding at September 30, 2018   1,067,527   $5.10 
Exercisable at September 30, 2018   559,232   $6.05 
   Number of
Options
   Weighted
Average
Exercise
Price
 
Outstanding at January 1, 2017   573,110   $6.94 
Granted   611,522    3.75 
Expired or canceled, during the period   (191,027)   6.64 
Forfeited, during the period   (13,017)   6.00 
Outstanding at December 31, 2017   980,588   $5.02 
Exercisable at December 31, 2017   448,890   $8.36
Schedule of stock-based compensation expense
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2018   2017   2018   2017 
Cost of revenue  $529   $333   $1,870   $3,279 
Sales and marketing expense   981    1,039    3,202    908 
Product development expense   14,380    3,396    33,640    36,628 
General and administrative expense   211,818    148,714    610,848    436,206 
Total stock compensation expense  $227,708   $153,482   $649,560   $477,021 

 

   Year ended
December 31,
 
   2017   2016 
Cost of revenue  $4,302   $117,147 
Sales and marketing expense   1,784    - 
Product development expense   166,783    - 
General and administrative expense   665,556    50,599 
Total stock-based compensation expense  $838,425   $167,746 
Schedule of restricted stock award activity

       Weighted 
       Average 
   Number of   Grant Date 
   RSAs   Fair Value 
Restricted Stock Awards:        
Unvested at January 1, 2018  158,571   $20.29 
Granted   -    - 
Expired or canceled, during the period   -    - 
Forfeited, during the period   -    - 
Unvested at September 30, 2018  158,571   $20.29 

   Number of
Restricted
Stock
Awards
   Weighted
Average
Grant Date
Fair Value
 
Outstanding at January 1, 2017   264,286   $20.29 
Granted   -    - 
Forfeited or canceled, during the period   (43,405)   20.29 
Vested   (62,310)   20.29 
Outstanding at December 31, 2017   158,571   $20.29